Advertisement

Supportive Care in Cancer

, Volume 21, Issue 1, pp 219–227 | Cite as

Symptoms in advanced pancreatic cancer are of importance for energy intake

  • Asta ByeEmail author
  • Marit S. Jordhøy
  • Grete Skjegstad
  • Oddlaug Ledsaak
  • Per Ole Iversen
  • Marianne Jensen Hjermstad
Original Article

Abstract

Purpose

Cancer cachexia and low energy intake (EI) probably contribute to weight loss in advanced pancreatic cancer (PC). However, little is known about the actual EI in this disease. Aims were to assess EI, weight loss and symptoms during the disease course and investigate associations between symptoms and EI.

Methods

Thirty-nine patients (21 males) with advanced PC were consecutively included and followed every 4 weeks until the end of life. A 24-h dietary recall was used to assess EI. The Edmonton Symptom Assessment System (ESAS) and the PC-specific health-related quality of life questionnaire (QLQ-PAN26) were used for symptom assessment.

Results

Median age was 62 years (48–88), WHO performance status 1 (0–2) and survival 5 months (1–25). Seventeen (44 %) patients had unresectable cancer, 16 (41 %) metastatic and six (15 %) recurrent disease. Upon inclusion, 37 (95 %) reported weight loss (median 4.0 kg per month). During follow-up, median weight loss per month was <1.0 kg. Forty to 65 % had EI <29 kcal/kg/day (cut-off value for weight maintenance) during the observation period but they did not lose more weight than patients with EI ≥ 29 kcal. Strong negative correlations (r range) were found between EI and pain (0.51–0.61), fatigue (0.54–0.67), oral dryness (0.61–0.64) and loss of appetite (0.53–0.71).

Conclusion

In this study, several symptoms influenced EI negatively. Low EI did not completely explain weight loss in this patient group, but careful monitoring and early follow-up of symptoms may be important interventions to reduce weight loss in advanced PC.

Keywords

Pancreatic cancer Weight loss Symptoms Food intake 

Notes

Acknowledgments

The authors wish to thank the clinical staff at the Department of Oncology and the Palliative Medicine Unit at Oslo University Hospital for their cooperation. We also want to thank Jurate Saltyte-Benth, Institute of Clinical Medicine, University of Oslo for all statistical assistance.

Conflict of Interest

The authors report no conflicts of interest. The authors alone have full control of all primary data and agree to allow the journal to review the data if requested.

References

  1. 1.
    Wigmore SJ, Plester CE, Richardson RA, Fearon KC (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75(1):106–109PubMedCrossRefGoogle Scholar
  2. 2.
    Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD (2008) Cachexia: a new definition. Clin Nutr 27(6):793–799. doi: S0261-5614(08)00113-1 [pii]10.1016/j.clnu.2008.06.013 PubMedCrossRefGoogle Scholar
  3. 3.
    Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489-495Google Scholar
  4. 4.
    Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR, Eisen T, O'Brien ME, Cunningham D, Andreyev HJ (2007) Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer 15(1):39–46. doi: 10.1007/s00520-006-0091-0 PubMedCrossRefGoogle Scholar
  5. 5.
    Bovio G, Bettaglio R, Bonetti G, Miotti D, Verni P (2008) Evaluation of nutritional status and dietary intake in patients with advanced cancer on palliative care. Minerva Gastroenterol Dietol 54(3):243–250PubMedGoogle Scholar
  6. 6.
    Bosaeus I, Daneryd P, Svanberg E, Lundholm K (2001) Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 93(3):380–383. doi: 10.1002/ijc.1332 [pii] PubMedCrossRefGoogle Scholar
  7. 7.
    Blum D, Omlin A, Baracos VE, Solheim TS, Tan BHL, Stone P, Kaasa S, Fearon K, Strasser F Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol/Hematol, Corrected Proof. doi:DOI:  10.1016/j.critrevonc.2010.10.004
  8. 8.
    Yavuzsen T, Walsh D, Davis MP, Kirkova J, Jin T, LeGrand S, Lagman R, Bicanovsky L, Estfan B, Cheema B, Haddad A (2009) Components of the anorexia-cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia. Support Care Cancer 17(12):1531–1541. doi: 10.1007/s00520-009-0623-5 PubMedCrossRefGoogle Scholar
  9. 9.
    Labori KJ, Hjermstad MJ, Wester T, Buanes T, Loge JH (2006) Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study. Support Care Cancer 14(11):1126–1133. doi: 10.1007/s00520-006-0067-0 PubMedCrossRefGoogle Scholar
  10. 10.
    Damerla V, Gotlieb V, Larson H, Saif MW (2008) Pancreatic enzyme supplementation in pancreatic cancer. J Support Oncol 6(8):393–396PubMedGoogle Scholar
  11. 11.
    Perez MM, Newcomer AD, Moertel CG, Go VL, Dimagno EP (1983) Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 52(2):346–352PubMedCrossRefGoogle Scholar
  12. 12.
    Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG (2005) Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 103(10):2189–2198PubMedCrossRefGoogle Scholar
  13. 13.
    Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24(21):3401–3407. doi: 24/21/3401 [pii] 10.1200/JCO.2005.04.5724 PubMedCrossRefGoogle Scholar
  14. 14.
    Bauer JD, Ash S, Davidson WL, Hill JM, Brown T, Isenring EA, Reeves M (2006) Evidence based practice guidelines for the nutritional management of cancer cachexia. Nutr Diet 63:S3–S32. doi: 10.1111/j.1747-0080.2006.00099.x CrossRefGoogle Scholar
  15. 15.
    Ferrucci L, Bell D, Thornton J, Black G, McCorkle R, Heimburger D, Saif M (2010) Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer:1-6. doi: 10.1007/s00520-010-1011-x
  16. 16.
    Blaker B, Aarsland M (1989) Mål og vekt for matvarer. Landsforeningen for kosthold & helse, [Oslo]Google Scholar
  17. 17.
    Lillegaard IT, Overby NC, Andersen LF (2005) Can children and adolescents use photographs of food to estimate portion sizes? Eur J Clin Nutr 59(4):611–617. doi: 1602119 [pii] 10.1038/sj.ejcn.1602119 PubMedCrossRefGoogle Scholar
  18. 18.
    Fagerli RA (2008) Matvaretabellen. Gyldendal undervisning, OsloGoogle Scholar
  19. 19.
    Saxholt E, Christensen AT, Møller A, Hartkopp HB, Hess Ygil, K, Hels, OH (2008) Danish food composition databank, revision 7Google Scholar
  20. 20.
    National food database, version 24/03/2010 (2010) http://www7.slv.se/livsmedelssok/
  21. 21.
    Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMedGoogle Scholar
  22. 22.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRefGoogle Scholar
  23. 23.
    Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, Buchler MW, Dervenis C, Fernandez Cruz L, Friess H, Grahm AL, Jeekel J, Laugier R, Meyer D, Singer MW, Tihanyi T (1999) Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer 35(6):939–941PubMedCrossRefGoogle Scholar
  24. 24.
    Selby D, Cascella A, Gardiner K, Do R, Moravan V, Myers J, Chow E (2010) A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton Symptom Assessment System. J Pain Symptom Manag 39(2):241–249CrossRefGoogle Scholar
  25. 25.
    Marin Caro MM, Laviano A, Pichard C (2007) Impact of nutrition on quality of life during cancer. Curr Opin Clin Nutr Metab Care 10(4):480–487PubMedCrossRefGoogle Scholar
  26. 26.
    Tong H, Isenring E, Yates P (2009) The prevalence of nutrition impact symptoms and their relationship to quality of life and clinical outcomes in medical oncology patients. Support Care Cancer 17(1):83–90PubMedCrossRefGoogle Scholar
  27. 27.
    Fayers PMAN, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual 3rd edn. EORTC Quality of Life Group Brussels, BelgiumGoogle Scholar
  28. 28.
    Cohen J (1988) Statistical power analysis for the behavioral sciences. Laurence Erlbaum, HillsdaleGoogle Scholar
  29. 29.
    Bovio G, Montagna G, Bariani C, Baiardi P (2009) Upper gastrointestinal symptoms in patients with advanced cancer: relationship to nutritional and performance status. Support Care Cancer 17(10):1317–1324PubMedCrossRefGoogle Scholar
  30. 30.
    Gibson RS (2005) Principles of nutritional assessment. Oxford University Press, New YorkGoogle Scholar
  31. 31.
    Johnson G, Salle A, Lorimier G, Laccourreye L, Enon B, Blin V, Jousset Y, Arnaud J-P, Malthiery Y, Simard G, Ritz P (2008) Cancer cachexia: measured and predicted resting energy expenditures for nutritional needs evaluation. Nutrition 24(5):443–450PubMedCrossRefGoogle Scholar
  32. 32.
    Bosaeus I (2008) Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer 16(5):447–451PubMedCrossRefGoogle Scholar
  33. 33.
    Berry DP, Charnley RM, Dervenis C, Kirk GR, Regan F, Yekebas EF, Imrie CW (2011) Pain management and nutritional support in nonresectable pancreatic cancer. In: Johnson CD, Imrie CW (eds) Pancreatic disease. Springer London, pp 73-77. doi: 10.1007/978-1-84882-118-7_8
  34. 34.
    Bruno MJ, Haverkort EB, Tijssen GP, Tytgat GN, van Leeuwen DJ (1998) Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 42(1):92–96PubMedCrossRefGoogle Scholar
  35. 35.
    Sarhill N, Mahmoud F, Walsh D, Nelson KA, Komurcu S, Davis M, LeGrand S, Abdullah O, Rybicki L (2003) Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer 11(10):652–659. doi: 10.1007/s00520-003-0486-0 PubMedCrossRefGoogle Scholar
  36. 36.
    Petruson KM, Silander EM, Hammerlid EB (2005) Quality of life as predictor of weight loss in patients with head and neck cancer. Head Neck 27(4):302–310PubMedCrossRefGoogle Scholar
  37. 37.
    Chang VT, Xia Q, Kasimis B (2005) The functional assessment of anorexia/cachexia therapy (FAACT) appetite scale in veteran cancer patients. J Support Oncol 3(5):377–382PubMedGoogle Scholar
  38. 38.
    Chate A (2006) A pilot audit of weight loss in upper gastrointestinal oncology outpatients. J Hum Nutr Diet 19(6):447–450PubMedCrossRefGoogle Scholar
  39. 39.
    Hopkinson JB, Wright DN, McDonald JW, Corner JL (2006) The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. J Pain Symptom Manag 32(4):322–331. doi: S0885-3924(06)00458-1 [pii] 10.1016/j.jpainsymman.2006.05.012 CrossRefGoogle Scholar
  40. 40.
    Davies AN, Broadley K, Beighton D (2002) Salivary gland hypofunction in patients with advanced cancer. Oral Oncol 38(7):680–685PubMedCrossRefGoogle Scholar
  41. 41.
    Sreebny LM, Schwartz SS (1997) A reference guide to drugs and dry mouth—2nd edition. Gerodontology 14(1):33–47PubMedCrossRefGoogle Scholar
  42. 42.
    Nieuw Amerongen AV, Veerman ECI (2003) Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 11(4):226–231PubMedGoogle Scholar
  43. 43.
    Hutton JL, Baracos VE, Wismer WV (2007) Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manag 33(2):156–165. doi: S0885-3924(06)00630-0 [pii]10.1016/j.jpainsymman.2006.07.017 CrossRefGoogle Scholar
  44. 44.
    Sanchez-Lara K, Sosa-Sanchez R, Green-Renner D, Rodriguez C, Laviano A, Motola-Kuba D, Arrieta O (2010) Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy. Nutr J 9:15. doi: 1475-2891-9-15 [pii]10.1186/1475-2891-9-15 PubMedCrossRefGoogle Scholar
  45. 45.
    Boltong A, Keast R (2012) The influence of chemotherapy on taste perception and food hedonics: a systematic review. Cancer Treat Rev 38(2):152–163PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Asta Bye
    • 1
    • 2
    Email author
  • Marit S. Jordhøy
    • 1
    • 3
  • Grete Skjegstad
    • 2
  • Oddlaug Ledsaak
    • 2
  • Per Ole Iversen
    • 4
    • 5
  • Marianne Jensen Hjermstad
    • 1
    • 6
  1. 1.Regional Centre for Excellence in Palliative CareOslo University HospitalOsloNorway
  2. 2.Department of Health, Nutrition and ManagementOslo and Akershus University College of Applied SciencesOsloNorway
  3. 3.The Cancer UnitInnlandet Hospital TrustGjøvikNorway
  4. 4.Department of NutritionUniversity of OsloOsloNorway
  5. 5.Department of HematologyOslo University HospitalOsloNorway
  6. 6.European Palliative Care Research Centre, Faculty of MedicineNorwegian University of Science and TechnologyTrondheimNorway

Personalised recommendations